Cancer Family
Head and Neck Neoplasm
CI-CAN-00000021Explore in graph →
Non-malignant1,571 active trials17 approved drugs142 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000021Explore in graph →
Clinical trials
6,372 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04221516 | Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 52 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT05898256 | Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 1 / Phase 2 | 20 | Guangxi Medical UniversityOTHER | 0 | Jun 12, 2023 | clinicaltrials |
| NCT05898373 | Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC | unknown | Phase 1 / Phase 2 | 120 | Peking Union Medical CollegeOTHER | 0 | Jun 12, 2023 | clinicaltrials |
| NCT05883007 | Dose Optimized BNCT for Head and Neck Cancer(ST-BNCT2001) | unknown | Phase 1 | 30 | Southern Tohoku BNCT Research CenterOTHER | 1 | Jun 5, 2023 | clinicaltrials |
| NCT05886075 | A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors | unknown | Early Phase 1 | 24 | Shanghai Yunying Medical TechnologyINDUSTRY | 1 | Jun 2, 2023 | clinicaltrials |
| NCT05876247 | Articulatory Adaptation Following Oral Cancer Treatment(SPOKE) | unknown | — | 50 | University Medical Center GroningenOTHER | 1 | May 30, 2023 | clinicaltrials |
| NCT03700905 | Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant Therapy(IMSTAR-HN) | unknown | Phase 3 | 276 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT03321539 | Phase Ⅲ Trial of Adjuvant Chemotherapy in Patients With N2-3 Nasopharyngeal Carcinoma | unknown | Phase 3 | 216 | Sun Yat-sen UniversityOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT05771025 | Effect of Hepatectomy on the Prognosis of Patients With Nasopharyngeal Carcinoma Liver Metastases | unknown | N/A | 55 | Fudan UniversityOTHER | 1 | May 19, 2023 | clinicaltrials |
| NCT03691441 | Comparative Effectiveness Trial of Transoral Head and Neck Surgery Followed by Adjuvant Radio(Chemo)Therapy Versus Primary Radiochemotherapy for Oropharyngeal Cancer | unknown | Phase 4 | 280 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | May 17, 2023 | clinicaltrials |
| NCT05861557 | Neoadjuvant Radiotherapy Combined With Toripalimab for Locally Advanced Head and Neck Squamous Cell Carcinoma | unknown | Phase 2 | 23 | Tianjin Medical University General HospitalOTHER | 1 | May 17, 2023 | clinicaltrials |
| NCT05857202 | Oxidative Stress and Inflammation Biomarkers in Surgically Treated Patients With Laryngeal Cancer | unknown | — | 100 | Clinical Centre of SerbiaOTHER | 1 | May 12, 2023 | clinicaltrials |
| NCT04031339 | Study of Clinical Outcomes of Thyroid Cancer(ITCO) | unknown | — | 15,000 | University of Roma La SapienzaOTHER | 1 | May 10, 2023 | clinicaltrials |
| NCT05843032 | 3D Ultrasound, Specimen Examination by Surgeon, and MRI in Surgical Margin Assessment | unknown | N/A | 27 | Rigshospitalet, DenmarkOTHER | 1 | May 9, 2023 | clinicaltrials |
| NCT04586088 | Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure | unknown | Phase 2 | 58 | Sun Yat-sen UniversityOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT05830240 | A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Relapsed/Refractory Head and Neck Cancer | unknown | Early Phase 1 | 9 | Shanghai Yunying Medical TechnologyINDUSTRY | 1 | Apr 26, 2023 | clinicaltrials |
| NCT05831917 | MRI - Guided Adaptive RadioTHerapy for Dysphagia in Head and Neck Cancer | unknown | N/A | 41 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Apr 26, 2023 | clinicaltrials |
| NCT05831930 | The Effect of Nitozumab in the Treatment of Head and Neck Squamous Cell Carcinoma | unknown | Early Phase 1 | 62 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Apr 26, 2023 | clinicaltrials |
| NCT05824312 | HRQOL in Locally Advanced Thyroid Carcinoma(LATCQOL) | unknown | — | 80 | Fujian Cancer HospitalOTHER_GOV | 1 | Apr 21, 2023 | clinicaltrials |
| NCT05821751 | The Effect of Prebiotic Inulin on Patients Affected by R/M HNSCC Treated With Immune Checkpoint Inhibitors(PRINCESS) | unknown | N/A | 40 | Fondazione del Piemonte per l'OncologiaOTHER | 1 | Apr 20, 2023 | clinicaltrials |
| NCT05170087 | Radiomic Analysis for Predicting Treatment Response and Clinical Outcomes in Malignancies | unknown | — | 1,200 | Sunnybrook Health Sciences CentreOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT05819593 | Evaluating Trends in Anaplastic Thyroid Cancer Patients' Clinical Study Experiences | unknown | — | 500 | Power Life Sciences Inc.INDUSTRY | 0 | Apr 19, 2023 | clinicaltrials |
| NCT05229315 | PD-1 Combined With Intensity Modulated Radiation Therapy in the Treatment of Intermediate-risk Nasopharyngeal Carcinoma | unknown | Phase 2 | 45 | XIANG YANQUNOTHER | 1 | Apr 13, 2023 | clinicaltrials |
| NCT05122507 | Liquid Biopsy of Head and Neck Cancer Patients in Blood and Saliva(KOHACIN) | unknown | — | 200 | Technical University of MunichOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05278364 | Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 184 | Shouyao Holdings (Beijing) Co. LTDOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05803915 | Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy | unknown | Phase 2 | 57 | Peking Union Medical College HospitalOTHER | 1 | Apr 7, 2023 | clinicaltrials |
| NCT05801770 | Discovering Factors in Head and Neck Cancer Patients' Clinical Study Experiences | unknown | — | 500 | Power Life Sciences Inc.INDUSTRY | 0 | Apr 6, 2023 | clinicaltrials |
| NCT02285530 | GDF15 Based TPF Induction Chemotherapy for OSCC Patients | unknown | Phase 2 | 72 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Apr 5, 2023 | clinicaltrials |
| NCT05796960 | European Multicenter Study on Surgical Management of Advanced Thyroid Cancer(ATCEU) | unknown | — | 3,917 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT03905369 | Focus on Values to Stimulate Shared Decisions | unknown | N/A | 128 | Radboud University Medical CenterOTHER | 1 | Apr 3, 2023 | clinicaltrials |
| NCT01829646 | Prediction of Outcome After Chemoradiotherapy for Head and Neck Cancer Using Functional Imaging and Tumor Biology | unknown | N/A | 120 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Mar 31, 2023 | clinicaltrials |
| NCT03418909 | Functional Outcome After Treatment for Oropharyngeal Squamous Cell Carcinoma | unknown | — | 44 | Rigshospitalet, DenmarkOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT05790200 | Cadonilimab (AK104) in the Treatment of Nasopharyngeal Carcinoma | unknown | Phase 2 | 30 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT04974866 | Tyrosine Kinase Inhibitors in Metastastic Adenoid Cystic Carcinoma | unknown | Phase 2 | 20 | Qingdao Central HospitalOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT03700476 | Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma(CONTINUUM) | unknown | Phase 3 | 425 | Sun Yat-sen UniversityOTHER | 1 | Mar 28, 2023 | clinicaltrials |
| NCT05097209 | Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma | unknown | Phase 2 | 200 | Wei JiangOTHER | 1 | Mar 23, 2023 | clinicaltrials |
| NCT04890132 | Vestibular Precision: Physiology & Pathophysiology | unknown | N/A | 90 | Massachusetts Eye and Ear InfirmaryOTHER | 1 | Mar 16, 2023 | clinicaltrials |
| NCT05211427 | Bitter Taste Receptors in Oropharynx Cancer | unknown | N/A | 20 | Thomas HummelOTHER | 1 | Mar 15, 2023 | clinicaltrials |
| NCT04543045 | Qualitative Exploration of Head & Neck Cancer Patient Reported Experience of Radiotherapy(H&NPRER-RAC) | unknown | — | 20 | The Christie NHS Foundation TrustOTHER | 1 | Mar 14, 2023 | clinicaltrials |
| NCT05766150 | Oral Microbioma and Oral Malignant Disease | unknown | — | 300 | Academisch Ziekenhuis MaastrichtOTHER | 1 | Mar 13, 2023 | clinicaltrials |
| NCT01590355 | A Phase II Randomized Trial for Early-stage Squamous Cell Carcinoma of the Oropharynx: Radiotherapy vs Trans-oral Robotic Surgery (ORATOR)(ORATOR) | unknown | Phase 2 | 68 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 2 | Mar 8, 2023 | clinicaltrials |
| NCT05429866 | Immunological Variables Associated to ICI Toxicity in Cancer Patients | unknown | Phase 2 | 441 | Jules Bordet InstituteOTHER | 1 | Mar 8, 2023 | clinicaltrials |
| NCT05758025 | A New Surgical Strategy to Protect the Inferior Parathyroid | unknown | N/A | 506 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Mar 7, 2023 | clinicaltrials |
| NCT04870905 | Tisleilizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma | unknown | Phase 2 | 100 | Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT03475953 | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors(REGOMUNE) | unknown | Phase 1 / Phase 2 | 747 | Institut BergoniéOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT00941538 | Cluster Randomized Controlled Screening Trial for NPC(CRCSTNPC) | unknown | N/A | 87,600 | Sun Yat-sen UniversityOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT05395429 | Clinical Evaluation of Genetron TERT/BRAF PCR Kit in Thyroid Cancer Patients | unknown | — | 1,000 | Genetron HealthINDUSTRY | 1 | Feb 23, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jun 18, 2023source: clinicaltrials